long intergenic non-protein coding RNA 2623Genealiases: []
Q-omics provides the consensus-scored LINC02623 profile across patient tissues and cancer cell-line models. LINC02623 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC02623 is differentially expressed in 10, with the highest sampling consensus in LUAD. Additionally, LINC02623 RNA expression shows 9,403 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight KIRC, LUAD, and PCPG as cancer lineages where LINC02623 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02623 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02623 survival associations across molecular data types. LINC02623 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02623 RNA expression–survival associations across cancer types. High LINC02623 expression shows unfavorable associations in STAD and LUSC, but favorable associations in KIRC, LUAD, LAML and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC02623 RNA expression.
This table summarizes LINC02623 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02623. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02623 shows lower tumor expression in LUAD, KICH, LUSC, BRCA, COAD and HNSC. The LUAD box plot shows higher LINC02623 RNA expression in normal versus tumor tissue (log2 FC = −0.414, t-test p < 0.001).
This table shows molecular features associated with LINC02623 in patient tissues and cancer cell lines. In patient samples, LINC02623 shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set.
